Peloton Therapeutics Overview

  • Founded
  • 2011

Founded
  • Status
  • Private

  • Employees
  • 64

Employees
  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $2.35B

  • Investors
  • 1

Peloton Therapeutics General Information

Description

Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. It is focused on targeting HIF-2a, a transcription factor which was thought to be intractable using a small molecule. The company's drug candidate, PT2977, has shown clinical proof of concept in patients with advanced or metastatic clear cell renal cell carcinoma.

Contact Information

Formerly Known As
Damascus Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • 2330 Inwood Road
  • Suite 226
  • Dallas, TX 75235
  • United States
+1 (972) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Peloton Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 11-Jul-2019 $2.35B 00000 00.000 Completed Clinical Trials - Phase 2
8. IPO 26-Apr-2019 00000 00000 Cancelled Clinical Trials - Phase 2
7. Later Stage VC (Series E) 20-Feb-2019 00000 00000 00000 Completed Generating Revenue
6. Later Stage VC (Series D) 14-Mar-2017 000.00 00000 00000 Completed Clinical Trials - Phase 2
5. Grant 05-Aug-2016 0000 000.00 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series C) 05-Nov-2014 000.00 000.00 00000 Completed Clinical Trials - Phase 1
3. Early Stage VC (Series B) 18-Dec-2013 000.00 000.00 000.00 Completed Startup
2. Grant $11M $18M Completed Startup
1. Early Stage VC (Series A) 27-Jul-2011 $18M $18M 0000 Completed Startup
To view Peloton Therapeutics’s complete valuation and funding history, request access »

Peloton Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E 00,000,000 00.000000 00.0 00.00 00.00 00 00.00 000
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 10,080,000 $0.000100 $0.1 $1.25 $1.25 1x $1.25 7.68%
Series A 17,100,000 $0.000100 $0.08 $1 $1 1x $1 13.03%
To view Peloton Therapeutics’s complete cap table history, request access »

Peloton Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Peloton Therapeutics Inc is a clinical stage biopharmaceutical company focused on translating novel scientific insights
Pharmaceuticals
Dallas, TX
64 As of 2019
00000
0.000 0000-00-00
000000&0 00000

000-00

or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
0000 000000000
Vienna, VA
00 As of 0000
000.00
000000000 000.00

00000

veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Peloton Therapeutics Competitors (89)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CEL-SCI Corporate Backed or Acquired Vienna, VA 00 000.00 000000000 000.00
00000 000 Formerly VC-backed Cambridge, MA 00 00000 000000&0 00000
000000000 00000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
0000000 Formerly PE-Backed Cambridge, MA 0000 00.000 00000000000 00.000
You’re viewing 5 of 89 competitors. Get the full list »

Peloton Therapeutics Patents

Peloton Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220081407-A1 Methods of preparing substituted indanes Inactive 11-Sep-2020 0000000000
EP-3953331-A4 Pyrazolesulfonamides as antitumor agents Pending 10-Apr-2019 0000000000
US-20220162193-A1 Pyrazolesulfonamides as antitumor agents Pending 10-Apr-2019 0000000000
EP-3953331-A1 Pyrazolesulfonamides as antitumor agents Pending 10-Apr-2019 0000000000
CA-3117563-A1 Solid dispersions and pharmaceutical compositions comprising a substituted indane and methods for the preparation and use thereof Pending 30-Oct-2018 C07C317/22
To view Peloton Therapeutics’s complete patent history, request access »

Peloton Therapeutics Executive Team (18)

Name Title Board Seat Contact Info
Zhaodan Cao Ph.D Director, Biology
Peter Stengel Ph.D Director, Chemical Development
John Josey Ph.D President, Chief Executive Officer & Board Member
Alan Musso Chief Financial Officer
James Tananbaum MD Advisor
You’re viewing 5 of 18 executive team members. Get the full list »

Peloton Therapeutics Board Members (14)

Name Representing Role Since
Brett Ringle JD Remeditex Ventures Board Member 000 0000
John Josey Ph.D Self President, Chief Executive Officer & Board Member 000 0000
You’re viewing 2 of 14 board members. Get the full list »

Peloton Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Peloton Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gershon Capital Venture Capital Minority 000 0000 000000 0
To view Peloton Therapeutics’s complete investors history, request access »